Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03125655 · ClinicalTrials.gov registry record

Regulation of Inflammatory Genes in Psoriasis

A clinical trial of Inflammation and Psoriasis, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
13
Enrollment target
1
Study location

NCT03125655 is a study of Inflammation and Psoriasis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03125655, a study of Inflammation and Psoriasis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
13 participants
Enrollment target
1
Study location

Study Summary

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Inflammatory markers

Study Locations (1)

Alabama

  • The Kirklin Clinic - Birmingham

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2014-04-22
Est. Completion 2027-04-28

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT03125655

The ClinicalTrials.gov registry entry for NCT03125655 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (95% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Inflammatory markers is the first listed.

NCT03125655 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT03125655 about?

NCT03125655 is a clinical study titled "Regulation of Inflammatory Genes in Psoriasis". Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers...

What is the current status of trial NCT03125655?

This trial is currently recruiting. The enrollment target is 13 participants. The study started on 2014-04-22. Estimated completion is 2027-04-28.

What conditions does trial NCT03125655 study?

This clinical trial studies the following conditions: Inflammation, Psoriasis.

What interventions are being tested in trial NCT03125655?

The interventions under investigation include: Inflammatory markers (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03125655?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03125655 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.